Invitrogen™ TFPI Human ELISA Kit

Description

The Human TFPI ELISA quantitates Hu TFPI in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu TFPI. Principle of the method The Human TFPI solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

Tissue factor pathway inhibitor (TFPI), also known as lipoprotein-associated coagulation inhibitor, is a protease inhibitor that regulates the tissue factor (TF)-dependent pathway of blood coagulation. TFPI is glycosylated and predominantly found in the vascular endothelium and plasma in both free forms and complexed with plasma lipoproteins. The coagulation process initiates with the formation of a factor VIIa-TF complex, which proteolytically activates additional proteases (factors IX and X) and ultimately leads to the formation of a fibrin clot. TFPI inhibits the activated factor X and VIIa-TF proteases in an autoregulatory loop.